Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Frequently asked questions
What sector does Intra-Cellular Therapies Inc (23I) operate in?
Intra-Cellular Therapies Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Intra-Cellular Therapies Inc (23I) current stock price?
As of the latest data, Intra-Cellular Therapies Inc stock price is €122.00, with a previous close of €122.00.
What is Intra-Cellular Therapies Inc (23I) current market capitalization?
Intra-Cellular Therapies Inc market cap is approximately 13.00 billion.
What is Intra-Cellular Therapies Inc (23I) Earnings Per Share (EPS)?
The trailing EPS is -€0.67.
Does Intra-Cellular Therapies Inc (23I) pay dividends?
No. Intra-Cellular Therapies Inc does not pay a dividend.
What is Intra-Cellular Therapies Inc (23I) beta (volatility) score?
Intra-Cellular Therapies Inc has a beta of 0.462, indicating lower volatility than the overall market.
